There is a large unmet medical need for patients suffering from functional Gastro-intestinal disorders. Naronapride, a late-development stage, Phase-3 ready, oral gastro-prokinetic drug in the class of 5-HT4 agonists has shown to be effective for a range of these disorders.

Ironwood Pharmaceuticals, Inc is a publicly traded pharmaceutical company. It was originally called Microbia, Inc.. Microbia was founded by postdocs from the lab of Gerald Fink at the Whitehead Institute to commercialize approaches that had been developed in the lab to improve industrial fermentation of fungi, to genetically engineer them to produce secondary metabolites more efficiently or to produce new ones as leads for drug discovery or as products for use in industry, and to identify drug targets in fungi for antifungal drug discovery. In 2002 the company hired John Talley to lead their antifungal drug discovery efforts, which at the time were focused on identifying small molecules that could inhibit fungal invasins, along with Mark Currie who had also worked at Searle division of Monsanto with Talley, and then had gone to Sepracor, and also Richard Bailey, who had run Monsanto's nutritional business. Currie directed the efforts that led to the discovery of linaclotide, which was based on an enterotoxin produced by some strains of Escherichia coli that cause traveler’s diarrhea.

Cara Therapeutics is an emerging biotechnology company focused on developing novel therapeutics to treat human diseases associated with pain and inflammation. Cara possesses both near-term clinical development opportunities combined with proprietary approaches to developing first-in-class novel therapeutics. Cara's most advanced patented compound, CR845, is currently undergoing clinical testing for acute pain and pruritis. This best-in-class compound possesses unique analgesic and anti-inflammatory activities appropriate for multiple therapeutic applications. In addition, Cara aims to develop a future pipeline of first-in-class molecules at novel analgesic and anti-inflammatory targets using its proprietary drug screening technology.

MicroPort Medical Technology (Shanghai) Co., Ltd., established on 2016-10-17, Business scope includes general items:In the field of medical technology(human stem cells,Except for the development and application of genetic diagnosis and treatment technology)technology development,technical consulting,technology transfer,Technical Services;Sales of Class I Medical Devices;Sales of Class II Medical Devices;Import and export;Technology Import and Export.(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license) licensed items:Class III medical device business.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments,The specific business items are subject to the approval documents or licenses of relevant departments)

MicroPort Medical Technology (Jiaxing) Co., Ltd., established on 2017-05-23, Business scope includes general items:engaged in the first category,Class II,Development of three types of medical devices,Production,Sales;In the field of medical technology(human stem cells,Except genetic diagnosis and treatment)technology development,technical consulting,technology transfer;engaged in import and export business.(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license).

The University of California is the nation's best public university system, delivering top-notch research and innovation to California (and the world).

Hengyi Biomedicine (Shanghai) Co., Ltd. is a Chinese company located in Shanghai. The firm engages in conducting biotechnological research and developmental services. It was founded by Heng Li.

Microbia an industrial biotechnology company, engages in the development, production, and commercialization of specialty ingredients and biomaterials utilizing fermentation technology. Its products include carotenoids, specialty ingredients, biopolymers, and other biomaterials. The company has a strategic alliance with Tate & Lyle Investments, Ltd. to develop and commercialize fermentation-derived renewable ingredients.

Ipsen Pharma SAS is a biopharmaceutical company that develops medicines in oncology, neuroscience and rare diseases. The company was founded by Henri Beaufour in 1929 and is headquartered in Boulogne-Billancourt, France.

Shenzhen Yixinda Medical Technology Co., Ltd., established on 1996-04-24, Business scope includes general business items:Domestic Trade(law,Administrative regulations,Except for items that are subject to approval prior to registration by decision of the State Council);Import and export of goods and technology(law,Except for items prohibited by administrative regulations;law,Projects restricted by administrative regulations must be licensed before they can be operated).,The licensing program is:Class II III6877Intervention equipment,Class III6866Medical polymer materials and products,II,III6864Medical hygiene materials and dressings,II,III6854operating room,emergency room,Consulting room equipment and appliances,II,Class III6821Production of medical electronic equipment.

Nanjing Drum Tower Hospital is a private company headquartered in China. The firm provides medical services.

Suzhou Frankman Medical Equipment Co., Ltd., established on 2003-06-11, Business scope includes licensed projects:Production of Class II Medical Devices;Production of Class III Medical Devices;Class III medical device business;Production of sterile equipment;Disinfection equipment sales(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments,Specific business projects are subject to approval results) General project:Sales of Class II Medical Devices;Production of Class I Medical Devices;Sales of Class I Medical Devices;Technology Import and Export;Import and export;Import and export agency;Technical Services,technology development,technical consulting,Technology Exchange,technology transfer,Technology Promotion(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license)

Sci Aide (Xiamen) Medical Equipment Co., Ltd., established on 2010-11-23, Business scope includes medical,Manufacturing of surgical and veterinary instruments;Other medical equipment and equipment manufacturing;second,Wholesale of Class III Medical Devices;second,Retailing of Class III Medical Devices;Wholesale of Class I Medical Devices;Retailing of Class I Medical Devices;Other unlisted professional and technical service industries(Not subject to permit approval);Other unspecified service industries(Items not subject to permit approval);Other unspecified manufacturing industries(Items not subject to permit approval);Import and export of various commodities and technologies(Import and export commodity catalog is not attached),Except for the goods and technologies that the state restricts the company to operate or prohibits the import and export of.

Yuhan Corp. engages in the manufacture of pharmaceutical, health foods, cosmetics and consumer products. It operates through the following business areas: Pharmaceutical, Household products and Active Pharmaceutical Ingredient (API). Its products include APIs and intermediates and finished products such as ethical drugs, over-the-counter drugs and others. Its services include custom development and manufacturing services and supply chain management. The company was founded by Il-Han New on June 20, 1926 and is headquartered Seoul, South Korea.